MICHAEL VOLK to Markov Chains
This is a "connection" page, showing publications MICHAEL VOLK has written about Markov Chains.
Connection Strength
0.300
-
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009 Dec; 50(6):1750-5.
Score: 0.077
-
Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation. Med Decis Making. 2008 Sep-Oct; 28(5):763-72.
Score: 0.071
-
A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008 Apr; 8(4):839-46.
Score: 0.068
-
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014 Feb; 60(2):290-7.
Score: 0.025
-
Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc. 2010 May; 42(4):1194-6.
Score: 0.020
-
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis. 2010 Sep; 42(9):642-9.
Score: 0.020
-
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010 Jan; 51(1):165-73.
Score: 0.019